AKR.L Regulatory News (AKR)

Embargoed: 0700hrs GMT, 31 January 2014

Akers Biosciences, Inc.

("ABI" or the "Company")

Directors' Holdings in Company

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

Akers Biosciences, Inc (AIM: AKR, NASDAQ:AKER), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces that, further to the issue of equity as announced on 23 January 2014, as of today the interests of those directors of the Company who hold shares are as follows:

*For the purposes of the AIM Rules only, Mr. Moran is classified as being indirectly interested in the Company through his 31.69% holding in Chubeworkx Guernsey Limited ("Chubeworkx"). Chubeworkx owns 512,820 shares (the "Chubeworkx Shares") or approximately 10.48% of the Company's issued share capital.

Pursuant to the United States Securities rules, Mr. Moran has no holding in the Company, has no voting control and has disclaimed any beneficial ownership with respect to the Chubeworkx Shares. 

** The mother of Dr Raymond Akers, Jr. owns 11,694 shares (the "Akers Shares") or approximately 0.24% of the issued share capital of the Company. The Company incorrectly disclosed on its website that Dr Raymond Akers, Jr. had an interest in the Akers Shares, albeit with the caveat that they were held by a family member. However, under the AIM Rules, the holdings of Dr Raymond Akers, Jr.'s mother are not disclosable and as such he is not classified as being interested in these shares either directly or indirectly.

Pursuant to the United States Securities rules, Dr Raymond Akers, Jr. has no holdings in the Company. 

Enquiries:

About Akers Biosciences, Inc.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com